Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
Topline data from Phase 3 ONWARD trials for Alumis’ ESK-001 in moderate-to-severe…
AM Best Downgrades Issuer Credit Rating of Gleaner Life Insurance Society; Maintains Under Review With Developing Implications Status on Credit Ratings
OLDWICK, N.J.--(BUSINESS WIRE)--#insurance--AM Best has downgraded the Long-Term Issuer Credit Rating to…
CGTN: How China contributes to global poverty reduction, drives modernization with developing nations
BEIJING, Nov. 19, 2024 /PRNewswire/ -- John Kimani, an expert from the Kenya…
